Oxford Cannabinoid Technologies present pipeline of cannabis-derived treatments for pain relief скачать в хорошем качестве

Oxford Cannabinoid Technologies present pipeline of cannabis-derived treatments for pain relief

Oxford Cannabinoid Technologies Holdings PLC's (LSE:OCTP) John Lucas talks to Proactive London about their pipeline of cannabis-derived pharmaceutical treatments for pain relief. The firm expect to report financial results in line with expectations as it updated on the progress of its drug pipeline. It spent £920,000 on research and development in the six months to the end of November. A total of £604,000 was invested in lead candidate OCT461201 for neuropathic and visceral pain. As at the end of the first half, the company was well-financed with £12mln in the bank. To understand more about the investment case for the firm, you can view a research analyst piece here:    • Oxford Cannabinoid Technologies targets a ...